Oncology Xagena
Non-clear cell renal cell carcinoma ( NccRCC ) and clear cell renal cell carcinoma with sarcomatoid differentiation ( sccRCC ) have historically been underrepresented in clinical trials. Even with ta ...
In KEYNOTE-189, Pembrolizumab ( Keytruda ) plus Pemetrexed ( Alimta ) and Platinum provided superior overall survival ( OS ) ( hazard ratio, HR 0.49, P less than 0.00001 ) and progression-free surviva ...
Clinical data for Larotrectinib ( Vitrakvi ), an oral, selective, and CNS-active TRK inhibitor, in adult and pediatric patients with TRK fusion cancers, were presented at the European Society for Medi ...
In a phase 1b trial, Avelumab ( Bavencio ) plus Axitinib ( Inlyta ) as first-line had encouraging antitumor activity for patients with advanced renal cell carcinoma ( aRCC ) ( Lancet Oncol 2018;19:451 ...
Role of aromatase inhibitors and Zoledronic acid ( Zometa ) as adjuvant treatment of premenopausal endocrine-responsive breast cancer patients is debated. Letrozole ( Femara ) has never been tested ...
The PARP inhibitor, Olaparib ( Lynparza ) has shown clinical activity in subsets of recurrent ovarian cancer patients. Researchers have hypothesized increased DNA damage by Olaparib may complement a ...
The PROSPER trial has shown a clinically and statistically significant improvement in metastasis-free survival ( hazard ratio, HR=0.292 [ 95% CI 0.241, 0.352 ], p less than 0.0001 ) with Enzalutamide ...
Activation of the PD-1 pathway has been implicated in resistance to BCG ( Bacillus Calmette–Guérin ) therapy. Pembrolizumab ( Keytruda ), a checkpoint inhibitor with significant activity in patients ...
Treatment with Nazartinib ( EGF816 ), a third generation epidermal growth factor receptor ( EGFR ) tyrosine kinase inhibitor ( TKI ), provided durable responses in adult patients with EGFR-mutated non ...
Although some patients with Platinum-pretreated metastatic urothelial cancer ( mUC ) demonstrated good responses to Nivolumab monotherapy, the response rate and survival were higher with combined Nivo ...
The pivotal phase 3 KEYNOTE-426 trial investigating Pembrolizumab ( Keytruda ), an anti-PD-1 therapy, in combination with Axitinib ( Inlyta ), tyrosine kinase inhibitor, met both primary endpoints of ...
The results from an interim analysis of KEYNOTE-057, a phase 2 trial evaluating Pembrolizumab ( Keytruda ), an anti-PD-1 therapy, for previously treated patients with high-risk non-muscle invasive bla ...
The U.S. Food and Drug Administration ( FDA ) has approved an expanded label for Keytruda, an anti-PD-1 therapy, in combination with Pemetrexed ( Alimta ) and Platinum chemotherapy for the first-line ...
Updated preliminary clinical data from an ongoing phase I dose escalation and expansion study evaluating the safety and efficacy of the combination of Monalizumab, a first-in-class monoclonal antibody ...
Radical metastasectomy followed by observation is a commonly used strategy in selected patients with metastatic renal cell carcinoma ( mRCC ). RESORT was the largest prospective study that assesse ...
